You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Drug Sales Trends for CIALIS


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for CIALIS (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
ON-LINE $9,617,263
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
ON-LINE 22,536
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
PRIVATE INSURANCE $8,715,820
SELF OR FAMILY $901,442
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for CIALIS
Drug Units Sold Trends for CIALIS

Annual Sales Revenues and Units Sold for CIALIS

These sales figures are drawn from a US national survey of drug expenditures

Market Analysis and Sales Projections for Cialis (Tadalafil)

Introduction to Cialis (Tadalafil)

Cialis, commonly known by its generic name tadalafil, is a prescription medication used to treat various conditions including erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. It is marketed by Eli Lilly and Company and has been a significant player in the pharmaceutical market since its introduction.

Current Market Size and Forecast

As of 2023, the tadalafil market was valued at USD 2.59 billion and is projected to reach USD 4.61 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 7.6% during the forecast period of 2024-2031[1].

However, another report suggests a more robust growth trajectory, with the tadalafil market valued at USD 6.25 billion in 2024 and expected to grow at a CAGR of 11.6% to reach USD 17.00 billion by 2034[4].

Impact of Generic Versions

The introduction of generic versions of Cialis has significantly impacted its sales. After Pfizer's Viagra lost exclusivity in December 2017, Cialis sales slid by 12% in the fourth quarter to $597.4 million. This trend continued as generic versions of Cialis were launched in 2018, leading to a sharp decline in brand sales. By 2022, Cialis sales were expected to dwindle to just $55 million, a drastic drop from its peak[2].

Market Segmentation

The tadalafil market is segmented based on several factors:

  • Purity: The market is segmented into different purity levels, such as 98% and above 98% purity[4].
  • Form: Tadalafil is available in various forms, including tablets and capsules[4].
  • Application: The primary applications include erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension[4].
  • Region: The market is analyzed across regions such as North America, Europe, Asia Pacific, Middle East and Africa, and South America[4].

Regional Analysis

North America is expected to dominate the tadalafil market, driven by high awareness of men's health issues and the availability of healthcare services. The Asia Pacific region also shows promising growth due to increasing healthcare access and awareness[4].

Key Players

The tadalafil market is competitive, with key players including:

  • Eli Lilly and Co. Pvt. Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Torrent Pharma
  • Camber Pharmaceuticals
  • Dr. Reddy’s Laboratories[4].

Market Drivers and Challenges

Drivers

  • Increasing awareness about men's health issues
  • Verified effectiveness and durable results of tadalafil
  • Expanding healthcare access in emerging markets[4].

Challenges

  • Possible adverse reactions to the medication
  • Competition from other erectile dysfunction drugs like Viagra
  • Economic factors such as price and limited access to healthcare in some regions[4].

Erectile Dysfunction Drugs Market Context

The broader erectile dysfunction drugs market, which includes Cialis, is expected to grow at a CAGR of 6.8% from 2023 to 2032, reaching USD 6.1 billion by 2032. Viagra (sildenafil citrate) currently holds a significant 58% revenue share in this market, while retail pharmacies dominate the distribution channels with a 46% market share[5].

Consumer Preference and Distribution

Consumer preference for erectile dysfunction drugs is influenced by factors such as efficacy, duration of action, and cost. Generic versions of these drugs, including tadalafil, are becoming increasingly popular due to their lower cost. For instance, generic sildenafil can start from as low as USD 8.5 per pill, making it more accessible to a wider audience[5].

Future Market Growth

Despite the challenges posed by generic competition, the tadalafil market is expected to grow significantly over the next decade. The market's growth will be driven by increasing awareness of men's health, the effectiveness of tadalafil, and expanding healthcare access in emerging markets.

"The length [of tadalafil's effect] can go up to 36 hours, with an average onset time of 30 minutes," which makes it a preferred choice for many patients[4].

Key Takeaways

  • The tadalafil market is valued at USD 2.59 billion in 2023 and is projected to reach USD 4.61 billion by 2031, growing at a CAGR of 7.6%[1].
  • Alternatively, the market is expected to reach USD 17.00 billion by 2034, growing at a CAGR of 11.6% from 2024[4].
  • Generic versions of Cialis have significantly impacted brand sales, leading to a decline in revenue.
  • North America dominates the market, but the Asia Pacific region shows promising growth.
  • Key drivers include increasing awareness of men's health and the verified effectiveness of tadalafil.

FAQs

1. What is the current market size of the tadalafil market?

The tadalafil market was valued at USD 2.59 billion in 2023[1].

2. What is the projected growth rate of the tadalafil market?

The market is projected to grow at a CAGR of 7.6% from 2024 to 2031, or alternatively at a CAGR of 11.6% from 2024 to 2034[1][4].

3. How has the introduction of generic versions affected Cialis sales?

The introduction of generic versions led to a significant decline in brand sales, with Cialis sales expected to dwindle to $55 million by 2022[2].

4. What are the primary applications of tadalafil?

The primary applications include erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension[4].

5. Which region dominates the tadalafil market?

North America currently dominates the tadalafil market, but the Asia Pacific region is expected to show significant growth[4].

Cited Sources:

  1. Verified Market Research - Tadalafil Market Size, Scope, Growth, Trends and Forecast
  2. FiercePharma - The Viagra effect: Sales of Lilly's ED drug Cialis slide after little blue pill goes generic
  3. Maia Research - Global Cialis- Drug Industry Research Report 2022, Competitive Landscape
  4. Prophecy Market Insights - Tadalafil Market Size Global Report, 2024 – 2034
  5. Market.US - Erectile Dysfunction Drugs Market Size | CAGR of 6.8%
Last updated: 2024-12-30

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.